A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 175 participants.

Also called NCT07839936

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 175 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07839936
  • EU CT 2026-525691-26-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07839936. Randomized; double masking; primary purpose treatment. Start 2026-09-24 (actual); primary completion 2028-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
Acronym
HEART-3
Condition
Atherosclerosis
Condition
Cardiovascular Disease
Condition
Hypercholesterolemia
Intervention (Drug)
VERVE-102
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct07839936
Content hash
1d2516313a4bbe58e4653997fb12cfafe116c40caa45bea8bccfa67b0fc11994